NVS Investor Day PR and slides: https://globenewswire.com/news-release/2017/11/13/1184851/0/en/Novartis-highlights-its-differentiated-late-stage-pipeline-at-the-R-D-update-and-investor-event.html https://www.novartis.com/sites/www.novartis.com/files/2017-11-r-d-day-investor-presentation.pdf NVS sees its “big-4” prospects as RTH258 (#msg-136129447); AMG 334/Erenumab (#msg-132026403); Cosentyx (#msg-123968598); and Ilaris/ACZ885/Canakinumab (#msg-136163917).